Valuation : Cipher Pharmaceuticals Inc

Market Cap 36Cr 26Cr 22Cr 21Cr 19Cr 2.48TCr 36Cr 248.28Cr 97Cr 1.25TCr 97Cr 95Cr 4.14TCr P/E 2026 *
12.6x
P/E 2027 * 11.4x
Enterprise Value 36Cr 26Cr 22Cr 21Cr 19Cr 2.48TCr 36Cr 248.28Cr 97Cr 1.25TCr 97Cr 95Cr 4.14TCr EV / Sales 2026 *
5.08x
EV / Sales 2027 * 4.35x
Free-Float
57.65%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 29/07/2019
Director of Finance/CFO - 10/08/2024
Director of Finance/CFO - 15/08/2022
Director TitleAgeSince
Chairman - 12/06/2019
Director/Board Member 78 21/06/2023
Director/Board Member - 21/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-22.72%-5.31% - - 26Cr
-0.13%-6.44%+60.47%+112.05% 1,04800Cr
+0.85%-0.81%+52.77%+63.15% 64TCr
-1.03%-3.58%+22.87%+73.29% 46TCr
-1.46%-3.52%+36.60%+38.39% 36TCr
-0.72%-2.06%+21.34%+37.92% 29TCr
-1.19%-0.98%+0.79%+12.29% 26TCr
-1.05%-1.57%+51.40%+68.55% 24TCr
+0.08%-0.22%-17.16%-53.76% 20TCr
-2.14%-0.30%+29.42%+89.10% 18TCr
Average -2.84%-0.72%+28.72%+49.00% 40.91TCr
Weighted average by Cap. -0.44%-1.92%+38.42%+65.53%

Financials

2026 *2027 *
Net sales 7.09Cr 5.1Cr 4.4Cr 4.12Cr 3.76Cr 487.55Cr 7.11Cr 49Cr 19Cr 246.11Cr 19Cr 19Cr 816.07Cr 8.27Cr 5.95Cr 5.13Cr 4.81Cr 4.39Cr 568.84Cr 8.3Cr 57Cr 22Cr 287.14Cr 22Cr 22Cr 952.12Cr
Net income 2.76Cr 1.99Cr 1.71Cr 1.6Cr 1.46Cr 189.77Cr 2.77Cr 19Cr 7.43Cr 96Cr 7.46Cr 7.29Cr 317.65Cr 3.25Cr 2.34Cr 2.02Cr 1.89Cr 1.72Cr 223.5Cr 3.26Cr 22Cr 8.75Cr 112.82Cr 8.78Cr 8.59Cr 374.11Cr
Net Debt - -
Logo Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-